Physician profile
Ambreen Sharaf
NPI 1235226275
$1,923.98
in general payments reported to CMS, 2019-2025
23 companies · $458 in 2025
The $458 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $235 · 2020: $41.63 · 2021: $237 · 2022: $273 · 2023: $294 · 2024: $385 · 2025: $458.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,137.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $539.55 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $353.77 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $224.89 | 2019-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $170.47 | 2021-2025 | Arexvy, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.48 | 2019-2025 | Jardiance |
| Exact Sciences Corporation | $69.20 | 2025 | Cologuard Collection Kit |
| Abbott Laboratories | $63.70 | 2022-2024 | Freestyle Libre 3 |
| Amgen INC. | $54.71 | 2024-2025 | Repatha, Otezla, Otezla |
| Astellas Pharma US INC | $41.23 | 2019-2024 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $36.79 | 2024 | |
| Althera Pharmaceuticals LLC | $33.61 | 2021-2022 | |
| Inspire Medical Systems, INC. | $32.86 | 2023-2024 | Inspire |
| Amarin Pharma, INC. | $27.86 | 2021 | |
| Shire North American Group INC | $22.01 | 2019 | |
| Sanofi-Aventis U.S. LLC | $19.08 | 2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $17.64 | 2024 | Voquezna |
| Biohaven Pharmaceutical Holding Company LTD. | $17.49 | 2022 | |
| Abbvie INC. | $16.61 | 2021 | |
| Medtronic Minimed, INC. | $16.38 | 2019 | |
| Novartis Pharmaceuticals Corporation | $14.68 | 2021 | |
| Redhill Biopharma INC. | $14.50 | 2020 | |
| Pfizer INC. | $13.31 | 2023 | |
| Merck Sharp & Dohme LLC | $13.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ambreen Sharaf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.